Trinity Biotech plc
TRIB
$0.94
$0.022.51%
NASDAQ
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -103.71% | 18.14% | -12.24% | -12.68% | 7.84% |
| Total Depreciation and Amortization | -77.86% | 101.75% | -52.69% | -74.60% | 185.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.41% | -5.51% | 74.58% | 4.24% | -10.34% |
| Change in Net Operating Assets | 178.11% | 158.40% | -79.97% | 988.89% | 106.90% |
| Cash from Operations | 60.98% | 105.25% | -5.59% | 170.86% | 134.99% |
| Capital Expenditure | -9.09% | -95.31% | 15.23% | -47.98% | -124.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.73% | 15.44% | -83.54% | 34.00% | 39.51% |
| Cash from Investing | 77.32% | -0.56% | -103.18% | 14.12% | 26.49% |
| Total Debt Issued | -70.02% | -- | -- | -- | -- |
| Total Debt Repaid | -8.45% | 2.28% | 94.63% | 12.28% | 98.06% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 12.93% | 35.05% | 37.18% | 29.86% | 69.10% |
| Cash from Financing | -79.22% | 27.35% | 81.93% | 40.85% | -154.82% |
| Foreign Exchange rate Adjustments | -614.29% | -1,228.57% | -83.72% | 118.44% | -16.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.01% | 67.74% | -179.08% | 78.87% | -825.40% |